Pressmeddelande -

Anders Jungbeck proposed as new member of the Board of Enzymatica

Enzymatica strengthens its Board with competency and experience from the pharmaceutical industry. Anders Jungbeck, vice president of the international pharmaceutical company Actavis, has been proposed as new member of the Board of Enzymatica. Anders Jungbeck has the past 29 years been working in both the Swedish and international pharmaceutical industry in companies as Glaxo, Draco, AstraZeneca and Ratiopharm.

- We are very pleased to have Anders Jungbeck to candidate for our Board. By having Anders on the Board we get a good gain in terms of experience from the international pharmaceutical market place, which is especially important in connection with our planned expansion in the Nordic region and Europe, says Michael Edelborg Christensen, CEO of Enzymatica.

- It feels really exhilarating to be proposed as a member of Enzymatica. It is a very interesting biotech company with an exciting pipeline of products, says Anders Jungbeck.

For more information on Enzymatica, contact:
Michael Edelborg Christensen, CEO at Enzymatica AB (publ), 0768-14 41 66,
michael.christensen@enzymatica.se 

Ämnen

  • Sjukdomar

Kategorier

  • Coldzyme
  • enzymatica
  • anders jungbeck
  • board of enzymatica
  • new board member

About Enzymatica AB (publ)
Enzymatica AB (publ) is a publicly traded biotechnology company focusing on research, development and sales of medical devices based on patented enzyme technology. Enzymatica utilizes a marine enzyme, a cold-adapted trypsine derived from deep-sea cod. The enzyme has a unique property that makes it super-active at about 37° C, making it superior in breaking down illness-related proteins, counteracting viral and bacterial infections and promoting healing processes. Enzymatica currently has two registered medical devices, PeriZyme chewing gum against periodontal diseases and ColdZyme Mouth Spray against common cold recently launched in pharmacies throughout the country.

About Enzymatica on the web
Enzymatica’s press room  »
Enzymatica’s website »
Enzymatica on LinkedIn »
Enzymatica on Twitter »
For Investors »
ColdZyme website »
ColdZyme on Facebook »

 

Kontakter

Relaterad media

  • Anders Jungbeck proposed as new member of the Board of Enzymatica
    Anders Jungbeck proposed as new member of the Board of Enzymatica
    Licens:
    Medieanvändning
    Filformat:
    .pdf
    mer info...
    Ladda ner
  • Anders Jungbeck proposed as new member of the Board of Enzymatica
    Licens:
    Medieanvändning
    Filformat:
    .docx
    mer info...
    Ladda ner

Relaterat innehåll

  • Annual General Meeting in Enzymatica AB (publ)

    At Enzymaticas Annual General Meeting today 6 May 2013, Christian Westin Jansson was elected new Chairman of the Board of Directors and Anders Jungbeck was elected new Board member. The meeting further resolved, inter alia, to implement an incentive program to employees and external Board members who work actively for the Company, and to authorize the Board to issue new shares.
    The AGM voted i

Fyll i din epostadress för att följa Enzymatica AB (publ)

När du väljer att skapa ett konto och följa ett nyhetsrum kommer dina personuppgifter behandlas av oss och av ägaren av nyhetsrummet för att du ska kunna motta nyheter och uppdateringar enligt dina bevakningsinställningar.

För att läsa mer om detta, var vänlig läs vår Integritetspolicy som berör vår behandling av dina personuppgifter, och Integritetspolicy för Contacts som berör behandlingen av dina personuppgifter från ägaren av nyhetsrummet du följer.

Vänligen notera att våra Användarvillkor gäller alla våra tjänster.

Du kan dra tillbaka ditt samtycke när som helst genom att avregistrera dig eller genom att ta bort ditt konto.
Kolla din inkorg

Mejl skickat till __email__. Klicka på länken i mejlet för att följa Enzymatica AB (publ).

Okej